System for the production of biocompatible, anti-cancer and antioxidant nanofibers based on acetogenin for applications in electronic devices

Abstract

A system (100) for producing biocompatible, anti-cancer and antioxidant acetogenin-based nanofibers for applications in electronic devices, comprising: a) a plant extract processing unit (102) configured to extract acetogenins from Annona muricata seeds; b) an isolation and purification unit (104) configured to isolate and purify acetogenins from the plant extract; c) a nanofiber synthesis unit (106) configured to process acetogenin-containing polymer solutions by electrospinning into acetogenin-based nanofibers (Act-NFs); and d) a device fabrication unit (108) configured to deposit the acetogenin-based nanofibers on a substrate to produce a memristive device.

Description

FIELD OF THE INVENTION

[0001] The present disclosure relates to a system for producing biocompatible, anti-cancer and antioxidant acetogenin-based nanofibers for applications in electronic devices. BACKGROUND OF THE INVENTION

[0002] The Annonaceae family, particularly Annona muricata, has received considerable attention in traditional medicine due to its therapeutic properties and antitumor potential. Annona muricata seeds are rich in acetogenins (ACGs), unique C35–C37 aliphatic secondary metabolites characterized by a terminal γ-lactone, tetrahydrofuran rings, and multiple hydroxyl groups. These naturally occurring bioactive compounds exhibit remarkable medicinal properties, including antimicrobial, antiviral, and anticancer activities. They can specifically target cancer cells by inhibiting NADH:ubiquinone oxidoreductase in the mitochondrial electron transport chain.

[0003] Despite the recognized therapeutic potential of acetogenins, their practical application has so far been limited by challenges in administration and bioavailability. At the same time, advances in nanotechnology are opening new avenues for drug delivery and biomedical applications. Nanofibers, with their high surface area, porosity, and mechanical properties similar to the extracellular matrix, represent an innovative platform for the incorporation of bioactive compounds. Electrospinning enables precise control of fiber properties through an electrohydrodynamic process using high-voltage fields.

[0004] Recent technology trends have also highlighted the potential of memristive devices as next-generation components for non-volatile memory, logic operations, and neuromorphic computing. Despite advances in these areas, a significant gap remains in systems that can effectively integrate naturally derived bioactive compounds such as acetogenins into functional nanofibers with electronic functions.

[0005] In light of the foregoing discussion, the present invention closes this gap by providing a comprehensive system for extracting and isolating acetogenins from Annona muricata seeds and incorporating them into electrospun nanofibers. These retain their biocompatible, anticancer, and antioxidant properties while simultaneously functioning as an active layer in memristive devices. This invention bridges the gap between natural bioactive compounds and advanced electronic applications, potentially enabling real-time and long-term health monitoring and other bioelectronic functions. Summary of the invention

[0006] The present invention relates to a system for producing biocompatible, anticancer, and antioxidant acetogenin-based nanofibers for electronic devices. The system consists of four main units: a plant extract preparation unit for extracting acetogenins from Annona muricata seeds, an isolation and purification unit for isolating and purifying the extracted acetogenins, a nanofiber synthesis unit for electrospinning polymer solutions with acetogenin incorporation, and a device manufacturing unit for fabricating memristive devices using acetogenin-based nanofibers.

[0007] The present disclosure aims to provide a system for producing biocompatible, anticancer, and antioxidant acetogenin-based nanofibers for electronic devices. The system comprises: a) a plant extract preparation facility for extracting acetogenins from Annona muricata seeds; b) an isolation and purification facility for isolating and purifying acetogenins from the plant extract; c) a nanofiber synthesis facility for electrospinning acetogenin-containing polymer solutions to form acetogenin-based nanofibers (Act-NFs); and d) a device fabrication facility for depositing the acetogenin-based nanofibers on a substrate to fabricate a memristive device.

[0008] An object of the present disclosure is to provide a system for producing biocompatible, anti-cancer and antioxidant acetogenin-based nanofibers for applications in electronic devices.

[0009] Another object of the present disclosure is to provide a system for extracting and isolating bioactive acetogenins from Annona muricata seeds and converting them into nanofibers with biocompatible, anticancer and antioxidant properties.

[0010] Another object of the present disclosure is to provide a system for fabricating memristive devices containing acetogenin-based nanofibers for resistive switching applications in electronic devices.

[0011] Another object of the present disclosure is to provide a comprehensive system that enables the production of biologically active acetogenin-based nanofibers with specific electrical properties suitable for integration into electronic devices.

[0012] To further clarify the advantages and features of the present disclosure, the invention will be explained in more detail with reference to specific embodiments illustrated in the accompanying drawings. These drawings show only typical embodiments of the invention and are therefore not to be considered as limiting its scope. The invention will be described and explained in more detail with reference to the accompanying drawings. SHORT DESCRIPTION OF THE FIGURE

[0013] These and other features, aspects, and advantages of the present disclosure will become better understood when the following detailed description is read with reference to the accompanying drawings, in which like characters represent like parts throughout. Fig. 1 shows a block diagram of a system for producing biocompatible, anti-cancer and antioxidant acetogenin-based nanofibers for applications in electronic devices according to an embodiment of the present disclosure.

[0014] Those skilled in the art will also appreciate that the elements in the drawings are shown for convenience and are not necessarily to scale. For example, the flowcharts illustrate the method by key steps to enhance understanding of aspects of the present disclosure. Furthermore, with respect to device construction, one or more components of the device may be represented in the drawings by conventional symbols. The drawing may show only the specific details relevant to understanding embodiments of the present disclosure in order not to clutter the drawing with details that would be readily apparent to those skilled in the art from the present description. DETAILED DESCRIPTION:

[0015] To facilitate an understanding of the principles of the invention, reference will now be made to the embodiment illustrated in the drawings and a clear description thereof. However, the scope of the invention is not limited thereby. Changes and further modifications to the illustrated system, as well as further applications of the principles of the invention, are possible, as would normally occur to one skilled in the art to which the invention pertains.

[0016] It will be understood by those skilled in the art that the foregoing general description and the following detailed description are exemplary and explanatory of the invention and are not intended to be limiting thereof.

[0017] References in this specification to "one aspect," "another aspect," or similar language mean that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present disclosure. Therefore, the language "in one embodiment," "in another embodiment," and similar language throughout this specification may or may not refer to the same embodiment.

[0018] The terms "comprises," "comprising," or other variations thereof are intended to cover non-exclusive inclusion, such that a process or method comprising a list of steps may include not only those steps, but also additional steps not expressly listed or inherent in that process or method. Likewise, the statement "comprises" for one or more devices, subsystems, elements, structures, or components does not exclude, without further limitation, the existence of other devices, subsystems, elements, structures, components, or additional devices, subsystems, elements, structures, or components.

[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. The systems, methods, and examples provided herein are for illustrative purposes only and should not be considered limiting.

[0020] Embodiments of the present disclosure will be described in detail below with reference to the accompanying drawings.

[0021] Fig. 1 shows a block diagram of a system for producing biocompatible, anti-cancer and antioxidant acetogenin-based nanofibers for applications in electronic devices according to an embodiment of the present disclosure.

[0022] With reference to Fig.1, the system (100) comprises: a) a plant extract production unit (102) configured to extract acetogenins from the seeds of Annona muricata; b) an isolation and purification unit (104) configured to isolate and purify acetogenins from the plant extract; c) a nanofiber synthesis unit (106) configured to electrospin polymer solutions containing acetogenin to form acetogenin-based nanofibers (Act-NFs); and d) a device fabrication unit (108) configured to deposit the acetogenin-based nanofibers on a substrate to create a memristive device.

[0023] In one embodiment, the plant extract production plant (102) comprises: a) a Soxhlet extraction system configured to extract compounds using methanol and ethyl acetate as solvents at 65°C; and b) an accelerated solvent extractor configured to perform an extraction at 2000 psi and 100°C using methanol and ethyl acetate as solvents.

[0024] In one embodiment, the isolation and purification unit (104) comprises: a) a reversed-phase high-performance liquid chromatography (RP-HPLC) system for separating acetogenins using a C-18 column with a methanol-water mobile phase; b) a fraction collector for collecting isolated acetogenin fractions; and c) a liquid chromatography-high-resolution mass spectrometry (LC-HRMS) system for analyzing and confirming the identity of isolated acetogenin compounds. The isolation and purification unit (104) further comprises an MS / MS system for characterizing the isolated acetogenin fractions.

[0025] In one embodiment, the nanofiber synthesis unit (106) comprises: a) a system for preparing a polymer solution that dissolves polyvinylpyrrolidone (PVP) in ethanol and incorporates acetogenins to form a homogeneous solution; b) an electrospinning device equipped with i) a high-voltage direct current source with an output of 0-30 kV; ii) a syringe pump system for dispensing the polymer-acetogenin solution at a controlled flow rate; and iii) a rotating cylindrical collection drum for collecting the electrospun nanofibers. The nanofiber synthesis unit (106) is configured to maintain electrospinning parameters that include a voltage of 26 kV, a solution flow rate of 30 µl / min, a needle-collector distance of 8 cm, and a drum speed of 700 rpm.

[0026] In one embodiment, the device fabrication unit (108) comprises: a) a radio frequency (RF) sputtering system for depositing aluminum layers on silicon dioxide / silicon substrates; b) an electrospinning system for depositing acetogenin-based nanofibers directly onto aluminum substrates; and c) a vacuum thermal evaporation system for depositing silver top electrodes onto the acetogenin-based nanofiber layers. The device fabrication unit (108) is configured for fabricating a memristive device with a structure of silver, acetogenin-based nanofibers, and aluminum for resistive switching applications.

[0027] In one embodiment, the system (100) further comprises a characterization unit (110) configured to analyze the properties of the acetogenin-based nanofibers and the memristive device, the characterization unit (110) comprising: a) a field emission scanning electron microscope for examining surface morphology; b) a Fourier transform infrared spectrometer for analyzing functional groups; c) thermal analysis equipment for evaluating thermal stability and phase transitions; and d) a source measurement unit connected to a manual testing station and configured to measure resistive circuits and synaptic properties.

[0028] In one embodiment, the system (100) is configured to produce acetogenin-based nanofibers with biocompatible, anti-cancer, and antioxidant properties suitable for memristive device applications.

[0029] The present invention describes a system for producing biocompatible, anticancer, and antioxidant acetogenin-based nanofibers for electronic devices. The system comprises a plant extract production facility that extracts acetogenins from Annona muricata seeds using two complementary extraction methods: Soxhlet extraction and accelerated solvent extraction. The Soxhlet extraction system operates at 65°C using methanol and ethyl acetate as solvents, while the accelerated solvent extractor operates at higher pressure (2000 psi) and higher temperature (100°C) to ensure comprehensive extraction of acetogenins from the plant material. This dual extraction process increases the yield and diversity of the acetogenins extracted from the seeds. The system's isolation and purification unit utilizes sophisticated analytical methods to isolate and characterize the extracted acetogenins.This facility includes a reversed-phase high-performance liquid chromatography (RP-HPLC) system with a C-18 column that separates acetogenins using a gradient of methanol and water as the mobile phase. The separated compounds are collected via a fraction collector, and their identity is confirmed by a high-resolution liquid chromatography-mass spectrometry (LC-HRMS) system. Further structural characterization is performed using tandem mass spectrometry (LC-MS / MS). The nanofiber synthesis unit converts the purified acetogenins into functional nanofibers using electrospinning. This unit includes a polymer solution preparation system that dissolves polyvinylpyrrolidone (PVP) in ethanol and processes the purified acetogenins into a homogeneous solution.The electrospinning device consists of a high-voltage direct current source capable of generating 0–30 kV, a syringe pump system that delivers the polymer-acetogenin solution at a controlled flow rate, and a rotating cylindrical collection drum that collects the electrospun nanofibers. The electrospinning parameters are precisely controlled at 26 kV voltage, 30 µl / min flow rate, 8 cm needle-to-collector distance, and 700 rpm drum speed to ensure uniform nanofiber formation. The system's device fabrication unit integrates the acetogenin-based nanofibers into functional memristive devices.This unit includes a radio frequency (RF) sputtering system for depositing aluminum layers on silicon dioxide / silicon substrates, an electrospinning system for directly depositing acetogenin-based nanofibers on aluminum substrates, and a vacuum thermal evaporation system for depositing silver top electrodes on the nanofiber layer. The resulting memristive device has a silver / acetogenin-based nanofiber / aluminum structure designed for resistive switching applications. The system also includes a comprehensive characterization unit with various analytical instruments for evaluating the properties of the acetogenin-based nanofibers and the resulting memristive devices.This unit includes a field emission scanning electron microscope for investigating surface morphology, a Fourier transform infrared spectrometer for functional group analysis, a thermal analyzer for assessing thermal stability and phase transitions, and a source measurement unit with a manual measurement station for measuring resistive circuits and synaptic properties. The characterization unit ensures that the acetogenin-based nanofibers retain their biocompatible, anti-cancer, and antioxidant properties while exhibiting the electrical properties required for electronic devices.

[0030] The system for producing biocompatible, anti-cancer and antioxidant acetogenin-based nanofibers for applications in electronic devices comprises several integrated units configured to perform specific operations.

[0031] The system includes a plant extract preparation unit configured to extract acetogenins from the seeds of Annona muricata. In this unit, the seeds are first collected, dried, and crushed into a fine powder. Extraction is performed using two different setups. In a Soxhlet extraction configuration, 2 grams of seed powder are placed in a thimble and 100 milliliters of methanol and ethyl acetate are added. The extraction is carried out for 3 hours at 65°C, after which the extract is collected and stored. In an accelerated extraction configuration, a Dionex ASE200 Accelerated Solvent Extractor is used. The powdered sample is mixed with Hydromatrix and transferred to an 11 ml stainless steel extraction thimble sealed at both ends with filter paper. Extraction is performed at 2000 psi and 100°C using methanol and ethyl acetate.The system includes a 5-minute equilibration phase followed by a 5-minute static phase. The sample is then rinsed with 60% solvent and purged with nitrogen. The extracted solvent is collected in 40-ml Teflon-capped vials, and a second extraction cycle is performed in the same manner.

[0032] The isolated plant extract is then transferred to the isolation and purification unit. This unit is configured with a reversed-phase high-performance liquid chromatography (RP-HPLC) system for the purification of acetogenins. A JASCO chromatography system with a PU-2087 Plus intelligent pump, an AS-2055 Plus automatic injector, and a UV-20270 Plus absorbance detector is used for this purpose. A Hibar® 250-4.6 C-18 column is used with a methanol:water mobile phase, starting at a ratio of 85:15 and gradually increasing to 95% methanol. The flow rate is maintained at 0.7 ml / min, and the detection wavelength is set to 220 nm for a total run time of 30 minutes. Fractions corresponding to the detected peaks are collected using an ADVANTEC CHF122sc fraction collector and the data are processed using the ChromNAV software system.Further annotation of the isolated fractions is performed using liquid chromatography-mass spectrometry (LC-HRMS). A Bruker Impact HD Q-TOF spectrophotometer connected to a Dionex UHPLC Ultimate 3000 system is used for this purpose. Electrospray ionization is used, operating in a scan range of 50–1200 m / z in positive ion mode. The setup includes an endplate offset of 500 V, a capillary voltage of 4000 V, a charging voltage of 2000 V, a drying heater set to 200 °C, and a drying gas flow of 4.0 l / min at a nebulizer pressure of 0.7 bar. The structure of acetogenin was determined using tandem mass spectrometry.

[0033] The system also includes a nanofiber synthesis unit for producing acetogenin-based nanofibers. A polymer solution is prepared by dissolving 10 wt% polyvinylpyrrolidone (PVP, MW ≈ 1,300,000) in 10 mL of ethanol for one hour with stirring. Subsequently, 0.5 mL of the acetogenin extract is added to the solution and stirred for another hour until a homogeneous mixture is obtained. This solution is filled into a 6 mL syringe with a 22-gauge stainless steel needle and connected to an electrospinning device. The electrospinning setup consists of a 26 kV high-voltage direct current power source, a syringe pump delivering the solution at a flow rate of 30 µL / min, a needle-to-collector distance of 8 cm, and a rotating cylindrical collector drum set at 700 rpm.Electrospinning is carried out for 3 hours and the acetogenin-based nanofibers (Act-NFs) are directly deposited on an aluminum substrate attached to the cylindrical drum.

[0034] The system also includes a fabrication unit for memristive devices. In this unit, an aluminum (500 nm) / SiO2 / Si substrate is fabricated using high-frequency sputtering. The Act-NFs layer is deposited onto the aluminum substrate using electrospinning. Subsequently, an approximately 100 nm thick silver top electrode is deposited over the nanofiber layer using a vacuum thermal deposition system (model: MCU-400D, manufacturer: Indian High Vacuum Pumps). The final device structure consists of a silver-acetogenin-based nanofiber-aluminum configuration suitable for resistive switching applications.

[0035] A characterization unit is integrated into the system to evaluate the properties of the nanofibers and the fabricated memristive device. This unit includes a Fourier transform infrared spectrometer (FTIR) (model: ALPHA 100508, manufacturer: Bruker, Germany) for functional group analysis, a field emission scanning electron microscope (FESEM, model: MIRA3 LMH) for surface morphology, and thermal analyzers (SDT Q600) for thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). Additionally, atomic force microscopy (AFM) is performed using a Park System Korea model NX10 to assess surface topography. Electrical characterization, including resistive switching and synaptic behavior, is performed using a Keithley 2602B source measurement unit connected to a manual test station.

[0036] The entire system is designed to produce acetogenin-based nanofibers with biocompatible, anti-cancer, and antioxidant properties tailored for application in memristive electronic devices.

[0037] The system includes an evaluation unit configured to assess the antioxidant, antibacterial and anticancer properties of acetogenins (ACGs) and acetogenin-based nanofibers (Act-NFs).

[0038] For the analysis of antioxidants, the device has a module for evaluating radical scavenging activity using DPPH. In this setup, 1 ml of different concentrations of ACGs and ANFs (0.2-1 mg / ml) is mixed with 1 ml of a 0.8 mM DPPH solution and kept in the dark for 30 minutes to prevent photocatalysis. The absorbance is measured at 517 nm, with DMSO as the reference and DPPH as the control. Gallic acid serves as the standard, and the percent inhibition is calculated using the following formula: % Inhibition = [(A0 - A T ) / A0] × 100, where AT is the absorbance of the test sample and A0 is the control.

[0039] In addition, a FRAP test module operates according to the iris and strain method. The module mixes 10 mM TPTZ in 40 mM HCl, 20 mM FeCl3, and acetate buffer in a ratio of 1:1:10 to form the FRAP reagent. In each well of a 96-well plate, 170 µl of this reagent is mixed with 20 µl of a 1 mg / ml sample, incubated for 30 minutes in the dark, and the absorbance is measured at 593 nm. Ascorbic acid serves as the standard. The relative reducing power is calculated as follows: [(AT-AC) / (Amax-Ac)] × 100, where AT is the absorbance of the sample, AC is the control, and Amax is the maximum absorbance of the standard.

[0040] The system also features an antibacterial test module that uses the agar diffusion technique to test activity against E. coli, S. aureus, and B. subtilis. Nutrient agar plates are inoculated with fresh bacterial culture, and 6.0 mm wells are filled with 25, 50, 75, and 100 µl of a 1 mg / ml compound solution. The plates are incubated for 24 hours at 37°C, and the zones of inhibition are recorded. Streptomycin (1 mg / ml) serves as a positive control, and DMSO as a negative control.

[0041] An integrated cytotoxicity assessment module is used to evaluate the anticancer potential in lung cancer (A549) and normal lung cell lines. The cells are inoculated at a concentration of 1 × 10 4Cells / ml were seeded and incubated for 24 hours at 37°C with 5% CO2. Act-NFs samples were added at concentrations of 20–100 µg / ml. After 24 hours, the medium was removed, and 20 µl of MTT reagent (5 mg / ml in PBS) was added. After 4 hours of incubation, formazan crystals were observed, the medium was discarded, and 200 µl of DMSO was added. The absorbance was measured at 550 nm using an ELISA plate reader.

[0042] Finally, an apoptosis detection module uses DAPI staining to examine the nuclear morphology of A549 lung cancer cells. Cells are fixed with 4% paraformaldehyde for 30 minutes, rinsed with PBS, and stained with 20 µl of DAPI (100 µg / ml) for 20 minutes at 37°C. After washing with PBS, cells are mounted on slides, and apoptotic features are observed under light and fluorescence microscopy.

[0043] The proposed system successfully synthesized biocompatible, anticancer, and antioxidant acetogenin-based nanofibers with electronic properties suitable for memristive applications. The characterization and evaluation of the prepared nanofibers regarding their biocompatible, anticancer, and antioxidant properties yielded the following key results.

[0044] The extraction and purification process yielded acetogenins from Annona muricata seeds, confirmed by HPLC analysis, HRMS, and MS / MS fragmentation patterns. The isolated compound exhibited a molecular ion peak with an m / z value of 610. MS / MS analysis of the selected fraction revealed the presence of two prominent fragments with a quasi-molecular ion peak at m / z 623.4894 [M + H] and additions at m / z 645.4719 [M + Na], corresponding to a molecular formula of C 37 H 66O7. FT-IR spectroscopy confirmed the presence of important acetogenin functional groups in the nanofibers, including hydroxyl groups (3339.7cm -1 ), aliphatic CH stretching vibrations (2973 and 2903 cm -1 ), carbonyl groups (1647.7 cm -1 ) and ether / lactone linkages (1292.3cm -1 Thermal analysis revealed a two-step degradation profile, with complete thermal degradation of the organic content occurring between 150–200°C. The synthesized acetogenin nanofibers (Act-NFs) exhibited a cross-linked one-dimensional architecture with uniform distribution and diameters of 450–550 nm, as confirmed by FESEM. This morphology mimics biological neural networks and enables efficient resistive switching properties.

[0045] The Act-NFs demonstrated higher antioxidant activity than pure acetogenin, with 88.53% inhibition in the DPPH test and 87.73% reducing power in the FRAP test. Biocompatibility tests showed excellent results, with Act-NFs maintaining 81.45% cell viability in normal lung cells even at the highest concentration tested (100 µg / ml). The Act-NFs demonstrated significant anticancer activity against the lung cancer cell line A549, reducing cell viability to 29.80% with 70.20% inhibition at an IC50 Wert of 68.25 µg / ml. DAPI staining confirmed the apoptotic mechanism and showed DNA fragmentation, chromatin condensation, and cell shrinkage in treated cancer cells.

[0046] The Ag / acetogenin NFs / Al memristive device showed a stable bipolar resistive switching behavior with good lifetime over 5000 cycles and a retention of at least 10- ...

[0047] The acetogenin-based nanofibers represent a significant advance, successfully combining the biological properties of natural compounds with electronic functionality. This integration creates a novel biomaterial with selective anticancer activity, excellent biocompatibility, and stable memristive properties, offering potential applications in both biomedicine and neuromorphic computing systems.

[0048] The drawings and the foregoing description show examples of embodiments. Those skilled in the art will recognize that one or more of the described elements may well be combined into a single functional element. Alternatively, certain elements may be separated into multiple functional elements. Elements of one embodiment may be added to another embodiment. For example, the order of the processes described herein may be changed and is not limited to the manner described herein. Furthermore, the actions of a flowchart need not be performed in the order shown; nor do all actions necessarily have to be performed. Also, actions that are not dependent on other actions may be performed in parallel with the other actions. The scope of the embodiments is in no way limited by these specific examples.Numerous variations, whether explicitly stated in the specification or not, such as differences in structure, dimensions, and material use, are possible.

[0049] The scope of the embodiments is at least as broad as indicated in the following claims.

[0050] Advantages, further benefits, and solutions to problems have been described above with reference to specific embodiments. However, the advantages, advantages, solutions to problems, and any components that may result in or enhance an advantage, advantage, or solution are not to be construed as critical, required, or essential features or components of any or all of the claims. REFERENCES 100 The system comprises:A) A plant extract preparation unit. 102 Plant for the Production of Plant Extracts 104 Isolation and cleaning unit 106 Nanofiber synthesis unit 108 device manufacturing units 110 Characterization Unit

Claims

[1] A system (100) for producing biocompatible, anti-cancer and antioxidant acetogenin-based nanofibers for applications in electronic devices, comprising: a) a plant extract processing unit (102) configured to extract acetogenins from Annona muricata seeds; b) an isolation and purification unit (104) configured to isolate and purify acetogenins from the plant extract; c) a nanofiber synthesis unit (106) configured to process acetogenin-containing polymer solutions by electrospinning into acetogenin-based nanofibers (Act-NFs); and d) a device fabrication unit (108) configured to deposit the acetogenin-based nanofibers on a substrate to produce a memristive device. [2] The system (100) of claim 1, wherein the plant extract production facility (102) comprises: a) a Soxhlet extraction system configured to extract compounds using methanol and ethyl acetate as solvents at 65°C; and b) an accelerated solvent extractor configured to perform the extraction at 2000 psi and 100°C using methanol and ethyl acetate as solvents. [3] The system (100) of claim 1, wherein the isolation and purification unit (104) comprises: a) a reversed-phase high-performance liquid chromatography (RP-HPLC) system configured to separate acetogenins using a C-18 column with a methanol-water mobile phase; b) a fraction collector configured to collect isolated acetogenin fractions; and c) a liquid chromatography-high-resolution mass spectrometry (LC-HRMS) system configured to analyze and confirm the identity of isolated acetogenin compounds. [4] The system (100) of claim 3, wherein the isolation and purification unit (104) further comprises an MS / MS system configured to characterize the isolated acetogenin. [5] The system (100) of claim 1, wherein the nanofiber synthesis unit (106) comprises: a) a polymer solution preparation system configured to dissolve polyvinylpyrrolidone (PVP) in ethanol and incorporate acetogenins to form a homogeneous solution; b) an electrospinning device configured with: i) a high voltage DC power source capable of generating 0-30 kV; ii) a syringe pump system configured to dispense the polymer-acetogenin solution at a controlled flow rate; and iii) a rotating cylindrical collection drum configured to collect the electrospun nanofibers. [6] The system (100) of claim 5, wherein the nanofiber synthesis unit (106) is configured to maintain electrospinning parameters including a voltage of 26 kV, a solution flow rate of 30 ul / min, a needle-collector distance of 8 cm, and a drum rotation speed of 700 rpm. [7] The system (100) of claim 1, wherein the device fabrication unit (108) comprises: a) a radio frequency (RF) sputtering system configured to deposit aluminum layers onto silicon dioxide / silicon substrates; b) an electrospinning system configured to deposit acetogenin-based nanofibers directly onto aluminum substrates; and c) a thermal vacuum evaporation system configured to deposit silver top electrodes onto the layer of acetogenin-based nanofibers. [8] The system (100) of claim 7, wherein the device manufacturing unit (108) is configured to manufacture a memristive device having a silver / acetogenin-based / aluminum-based nanofiber structure for resistive switching applications. [9] The system (100) of claim 1, further comprising a characterization unit (110) configured to analyze the properties of the acetogenin-based nanofibers and the memristive device, the characterization unit (110) comprising: a) a field emission scanning electron microscope for examining surface morphology; b) a Fourier transform infrared spectrometer for analyzing functional groups; c) thermal analysis equipment for evaluating thermal stability and phase transitions; and d) a source measurement unit connected to a manual testing station and configured to measure resistive circuits and synaptic properties. [10] The system (100) of claim 1, wherein the system is configured to produce acetogenin-based nanofibers having biocompatible, anti-cancer, and antioxidant properties suitable for applications in memristive devices.

Images